Literature DB >> 27696303

MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR.

Ranran Zhang1, Heather Hardin1, Wei Huang1, Jidong Chen1, Sofia Asioli2, Alberto Righi3, Francesca Maletta4, Anna Sapino4, Ricardo V Lloyd5.   

Abstract

Long non-coding RNAs (lncRNAs) are important for transcription and for epigenetic or posttranscriptional regulation of gene expression and may contribute to carcinogenesis. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), an lncRNA involved in the regulation of the cell cycle, cell proliferation, and cell migration, is known to be deregulated in multiple cancers. Here, we analyzed the expression of MALAT1 on 195 cases of benign and malignant thyroid neoplasms by using tissue microarrays for RNA in situ hybridization (ISH) and real-time PCR. MALAT1 is highly expressed in normal thyroid (NT) tissues and thyroid tumors, with increased expression during progression from NT to papillary thyroid carcinomas (PTCs) but is downregulated in poorly differentiated thyroid cancers (PDCs) and anaplastic thyroid carcinomas (ATCs) compared to NT. Induction of epithelial to mesenchymal transition (EMT) by transforming growth factor (TGF)-beta in a PTC cell line (TPC1) led to increased MALAT1 expression, supporting a role for MALAT1 in EMT in thyroid tumors. This is the first ISH study of MALAT1 expression in thyroid tissues. It also provides the first piece of evidence suggesting MALAT1 downregulation in certain thyroid malignancies. Our findings support the notion that ATCs may be molecularly distinct from low-grade thyroid malignancies and suggest that MALAT1 may function both as an oncogene and as a tumor suppressor in different types of thyroid tumors.

Entities:  

Keywords:  In situ hybridization; Long non-coding RNA; MALAT1; Papillary thyroid carcinoma; RT-PCR; Thyroid carcinoma

Mesh:

Substances:

Year:  2017        PMID: 27696303      PMCID: PMC5313332          DOI: 10.1007/s12022-016-9453-4

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  24 in total

Review 1.  Long Noncoding RNAs: Insights from Biological Features and Functions to Diseases.

Authors:  Xiaolei Li; Zhiqiang Wu; Xiaobing Fu; Weidong Han
Journal:  Med Res Rev       Date:  2012-02-08       Impact factor: 12.944

2.  Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors.

Authors:  Yuri E Nikiforov; Raja R Seethala; Giovanni Tallini; Zubair W Baloch; Fulvio Basolo; Lester D R Thompson; Justine A Barletta; Bruce M Wenig; Abir Al Ghuzlan; Kennichi Kakudo; Thomas J Giordano; Venancio A Alves; Elham Khanafshar; Sylvia L Asa; Adel K El-Naggar; William E Gooding; Steven P Hodak; Ricardo V Lloyd; Guy Maytal; Ozgur Mete; Marina N Nikiforova; Vania Nosé; Mauro Papotti; David N Poller; Peter M Sadow; Arthur S Tischler; R Michael Tuttle; Kathryn B Wall; Virginia A LiVolsi; Gregory W Randolph; Ronald A Ghossein
Journal:  JAMA Oncol       Date:  2016-08-01       Impact factor: 31.777

3.  Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas.

Authors:  Darya Buehler; Heather Hardin; Weihua Shan; Celina Montemayor-Garcia; Patrick S Rush; Sofia Asioli; Herbert Chen; Ricardo V Lloyd
Journal:  Mod Pathol       Date:  2012-08-17       Impact factor: 7.842

Review 4.  Papillary thyroid carcinoma: an update.

Authors:  Virginia A LiVolsi
Journal:  Mod Pathol       Date:  2011-04       Impact factor: 7.842

5.  Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas.

Authors:  J Braun; C Hoang-Vu; H Dralle; S Hüttelmaier
Journal:  Oncogene       Date:  2010-05-24       Impact factor: 9.867

6.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

7.  Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205.

Authors:  Hiroshi Hirata; Yuji Hinoda; Varahram Shahryari; Guoren Deng; Koichi Nakajima; Z Laura Tabatabai; Nobuhisa Ishii; Rajvir Dahiya
Journal:  Cancer Res       Date:  2015-01-19       Impact factor: 12.701

8.  Specific microRNAs are downregulated in human thyroid anaplastic carcinomas.

Authors:  R Visone; P Pallante; A Vecchione; R Cirombella; M Ferracin; A Ferraro; S Volinia; S Coluzzi; V Leone; E Borbone; C-G Liu; F Petrocca; G Troncone; G A Calin; A Scarpa; C Colato; G Tallini; M Santoro; C M Croce; A Fusco
Journal:  Oncogene       Date:  2007-06-11       Impact factor: 9.867

9.  The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type.

Authors:  Jaroslaw Jendrzejewski; Huiling He; Hanna S Radomska; Wei Li; Jerneja Tomsic; Sandya Liyanarachchi; Ramana V Davuluri; Rebecca Nagy; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-14       Impact factor: 11.205

10.  BRAF-Activated Long Noncoding RNA Modulates Papillary Thyroid Carcinoma Cell Proliferation through Regulating Thyroid Stimulating Hormone Receptor.

Authors:  Haitao Zheng; Meng Wang; Lixin Jiang; Haidi Chu; Jinchen Hu; Jinyao Ning; Baoyuan Li; Dong Wang; Jie Xu
Journal:  Cancer Res Treat       Date:  2015-08-12       Impact factor: 4.679

View more
  19 in total

1.  The lncRNA UNC5B-AS1 promotes proliferation, migration, and invasion in papillary thyroid cancer cell lines.

Authors:  Yinghao Wang; Adheesh Bhandari; Jizhao Niu; Fan Yang; Erjie Xia; Zhihan Yao; Yixiang Jin; Zhouci Zheng; Shixu Lv; Ouchen Wang
Journal:  Hum Cell       Date:  2019-02-25       Impact factor: 4.174

2.  Long Non-coding RNA Expression in Anaplastic Thyroid Carcinomas.

Authors:  Yanping Wang; Heather Hardin; Ying-Hsia Chu; Karla Esbona; Ranran Zhang; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

3.  Phosphorylated Mechanistic Target of Rapamycin (p-mTOR) and Noncoding RNA Expression in Follicular and Hürthle Cell Thyroid Neoplasm.

Authors:  Adam Covach; Sanjay Patel; Heather Hardin; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

4.  Hypoxia induces cancer cell-specific chromatin interactions and increases MALAT1 expression in breast cancer cells.

Authors:  Joshua K Stone; Jung-Hyun Kim; Lana Vukadin; Alexander Richard; Hannah K Giannini; Ssang-Taek Steve Lim; Ming Tan; Eun-Young Erin Ahn
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

5.  Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1.

Authors:  Lisha Gou; Huawei Zou; Beibei Li
Journal:  Cancer Biol Ther       Date:  2019-09-10       Impact factor: 4.742

Review 6.  Long non-coding RNA implicated in the invasion and metastasis of head and neck cancer: possible function and mechanisms.

Authors:  Xiaobo Luo; Yan Qiu; Yuchen Jiang; Fangman Chen; Lu Jiang; Yu Zhou; Hongxia Dan; Xin Zeng; Yu L Lei; Qianming Chen
Journal:  Mol Cancer       Date:  2018-01-24       Impact factor: 27.401

7.  LncRNAs as Potential Therapeutic Targets in Thyroid Cancer.

Authors:  Zeeshan Javed; Faiez Ahmed Shah; Sadegh Rajabi; Qamar Raza; Zaheer Iqbal; Mukhtar Ullah; Touqeer Ahmad; Bahare Salehi; Mehdi Sharifi-Rad; Raffaele Pezzani; Farooq Yaqoob; Haleema Sadia; Marcello Iriti; Javad Sharifi-Rad; William C Cho
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01

Review 8.  The Role of Long Non-Coding RNAs in Thyroid Cancer.

Authors:  Xuejiao Peng; Kun Zhang; Li Ma; Junfeng Xu; Weiqin Chang
Journal:  Front Oncol       Date:  2020-06-11       Impact factor: 6.244

Review 9.  Role of Regulatory Non-Coding RNAs in Aggressive Thyroid Cancer: Prospective Applications of Neural Network Analysis.

Authors:  Asumi Iesato; Carmelo Nucera
Journal:  Molecules       Date:  2021-05-19       Impact factor: 4.411

Review 10.  Current research on head and neck cancer-associated long noncoding RNAs.

Authors:  Wei Song; Yimin Sun; Jie Lin; Xiaoqin Bi
Journal:  Oncotarget       Date:  2017-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.